Somewhat Positive Media Coverage Somewhat Unlikely to Impact Albany Molecular Research (AMRI) Share Price

Media headlines about Albany Molecular Research (NASDAQ:AMRI) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Albany Molecular Research earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.4318078519138 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Albany Molecular Research (NASDAQ AMRI) opened at $21.74 on Thursday. The stock has a market cap of $937.41, a P/E ratio of -15.20 and a beta of 1.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.37 and a current ratio of 0.68. Albany Molecular Research has a 1-year low of $13.01 and a 1-year high of $22.17.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Albany Molecular Research (AMRI) Share Price” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at

About Albany Molecular Research

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Insider Buying and Selling by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply